Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Expanded in Metastatic Breast Cancer
NCT03344965Phase 2Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Apr 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in breast cancer, sponsored by Beth Israel Deaconess Medical Center. Started Apr 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03344965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344965.